» Articles » PMID: 18205713

Vitiligo Pathogenesis: Autoimmune Disease, Genetic Defect, Excessive Reactive Oxygen Species, Calcium Imbalance, or What Else?

Overview
Journal Exp Dermatol
Specialty Dermatology
Date 2008 Jan 22
PMID 18205713
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

The pathobiology of vitiligo has been hotly disputed for as long as one remembers, and has been a magnet for endless speculation. Evidently, the different schools of thought--ranging, e.g. from the concept that vitiligo essentially is a free-radical disorder to that of vitiligo being a primary autoimmune disease--imply very different consequences for the best therapeutic strategies that one should adopt. As a more effective therapy for this common, often disfiguring pigmentary disorder is direly needed, we must strive harder to settle the pathogenesis debate definitively--on the basis of sound experimental evidence, rather than by a war of dogmatic theories. Recognizing, however, that it is theories which tend to guide our experimental designs and choice of study parameters, the various pathogenesis theories on the market deserve to be critically, yet unemotionally re-evaluated. This Controversies feature invites you to do so, and to ask yourself: is there something important or worthwhile exploring in other pathogenesis scenarios than those already favoured by you that may help you improve your own study design, next time you have a fresh look at vitiligo? Vitiligo provides a superb model for the study of many fundamental problems in skin biology and pathology. Therefore, even if it later turns out that, as far as your own vitiligo pathogenesis concept is concerned, you have barked-up the wrong tree most of the time, chances are that you shall anyway have generated priceless new insights into skin function along the way.

Citing Articles

An Overview of the Biological Complexity of Vitiligo.

Matarrese P, Puglisi R, Mattia G, Samela T, Abeni D, Malorni W Oxid Med Cell Longev. 2024; 2024:3193670.

PMID: 39735711 PMC: 11671640. DOI: 10.1155/omcl/3193670.


Low-Dose Melittin Enhanced Pigment Production Through the Upregulation of Tyrosinase Activity and Dendricity in Melanocytes by Limiting Oxidative Stress: A Therapeutic Implication for Vitiligo.

Tembhre M, Shipra Antioxidants (Basel). 2024; 13(11).

PMID: 39594565 PMC: 11590868. DOI: 10.3390/antiox13111424.


Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis.

Ramot Y, Rosenberg V, Zhou L, Harbers S Adv Ther. 2024; 41(7):2890-2906.

PMID: 38802636 PMC: 11213800. DOI: 10.1007/s12325-024-02875-0.


Serum cytokine profiles predict response to systemic glucocorticoid in active vitiligo.

Wang X, Fan J, He K, Chen J, Li S Postepy Dermatol Alergol. 2024; 41(2):189-196.

PMID: 38784928 PMC: 11110216. DOI: 10.5114/ada.2024.138672.


Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.

Pranic S, Pulumati A, Vukovic D Syst Rev. 2024; 13(1):110.

PMID: 38641831 PMC: 11027385. DOI: 10.1186/s13643-024-02522-3.